scholarly journals A basal stem cell signature identifies aggressive prostate cancer phenotypes

2015 ◽  
Vol 112 (47) ◽  
pp. E6544-E6552 ◽  
Author(s):  
Bryan A. Smith ◽  
Artem Sokolov ◽  
Vladislav Uzunangelov ◽  
Robert Baertsch ◽  
Yulia Newton ◽  
...  

Evidence from numerous cancers suggests that increased aggressiveness is accompanied by up-regulation of signaling pathways and acquisition of properties common to stem cells. It is unclear if different subtypes of late-stage cancer vary in stemness properties and whether or not these subtypes are transcriptionally similar to normal tissue stem cells. We report a gene signature specific for human prostate basal cells that is differentially enriched in various phenotypes of late-stage metastatic prostate cancer. We FACS-purified and transcriptionally profiled basal and luminal epithelial populations from the benign and cancerous regions of primary human prostates. High-throughput RNA sequencing showed the basal population to be defined by genes associated with stem cell signaling programs and invasiveness. Application of a 91-gene basal signature to gene expression datasets from patients with organ-confined or hormone-refractory metastatic prostate cancer revealed that metastatic small cell neuroendocrine carcinoma was molecularly more stem-like than either metastatic adenocarcinoma or organ-confined adenocarcinoma. Bioinformatic analysis of the basal cell and two human small cell gene signatures identified a set of E2F target genes common between prostate small cell neuroendocrine carcinoma and primary prostate basal cells. Taken together, our data suggest that aggressive prostate cancer shares a conserved transcriptional program with normal adult prostate basal stem cells.

2014 ◽  
Vol 1 (2) ◽  
pp. 96-99 ◽  
Author(s):  
Seth Lipka ◽  
Jorge Hurtado-Cordovi ◽  
Boris Avezbakiyev ◽  
Lester Freedman ◽  
Toshimasa Clark ◽  
...  

2019 ◽  
Vol 145 (12) ◽  
pp. 3453-3461 ◽  
Author(s):  
Mohammed Alshalalfa ◽  
Yang Liu ◽  
Alexander W. Wyatt ◽  
Ewan A. Gibb ◽  
Harrison K. Tsai ◽  
...  

Metabolites ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. 82 ◽  
Author(s):  
Bei Gao ◽  
Hui-Wen Lue ◽  
Jennifer Podolak ◽  
Sili Fan ◽  
Ying Zhang ◽  
...  

As the most common cancer in men, prostate cancer is molecularly heterogeneous. Contributing to this heterogeneity are the poorly understood metabolic adaptations of the two main types of prostate cancer, i.e., adenocarcinoma and small cell neuroendocrine carcinoma (SCNC), the latter being more aggressive and lethal. Using transcriptomics, untargeted metabolomics and lipidomics profiling on LASCPC-01 (prostate SCNC) and LNCAP (prostate adenocarcinoma) cell lines, we found significant differences in the cellular phenotypes of the two cell lines. Gene set enrichment analysis on the transcriptomics data showed 62 gene sets were upregulated in LASCPC-01, while 112 gene sets were upregulated in LNCAP. ChemRICH analysis on metabolomics and lipidomics data revealed a total of 25 metabolite clusters were significantly different. LASCPC-01 exhibited a higher glycolytic activity and lower levels of triglycerides, while the LNCAP cell line showed increases in one-carbon metabolism as an exit route of glycolytic intermediates and a decrease in carnitine, a mitochondrial lipid transporter. Our findings pinpoint differences in prostate neuroendocrine carcinoma versus prostate adenocarcinoma that could lead to new therapeutic targets in each type.


Sign in / Sign up

Export Citation Format

Share Document